Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: J Vasc Surg. 2011 Jan 12;53(3):668–675. doi: 10.1016/j.jvs.2010.08.029

Table 2.

Baseline demographic information by response category among the different assays

AA aggregometry (n=80) Responders (n=65) Initial PR (n=11) Persistent PR (n=4) P
 Age (yrs) 64.7 63.6 67.6 0.31
 Race (% Black, White, Hispanic) 19%, 68%, 13% 9%, 91%, 0% 50%, 50%, 0% 0.23
 ASA dose (% 325 mg) 86% 91% 50% 0.12
 Clopidogrel use (%) 26% 36% 0% 0.37
 NSAID use (%) 18% 9% 0% 0.84
 History of Smoking (%) 92% 82% 100% 0.43
 Current Smoking (%) 45% 56% 25% 0.65
 Hypertension (%) 82% 82% 100% 0.64
 CAD (%) 22% 18% 25% 0.93
 Diabetes (%) 47% 0% 25% 0.01
 Body Mass Index (kg/m2) 29.8 31.7 26.5 0.33
 Hematocrit (%) 40.9% 52.5% 35.8% 0.02
 hsCRP (mg/L) 2.83 2.98 4.27 0.61
ADP aggregometry (n=80) Responders (n=33) Initial PR (n=25) Persistent PR (n=22) P
 Age (yrs) 64.8 62.9 65.7 0.50
 Race (% Black, White, Hispanic) 15%, 79%, 6% 20%, 60%, 20% 23%, 68%, 9% 0.44
 ASA dose (% 325 mg) 82% 92% 82% 0.50
 Clopidogrel use (%) 36% 28% 9% 0.08
 NSAID use (%) 9% 7% 27% 0.20
 History of Smoking (%) 91% 92% 91% 0.99
 Current Smoking (%) 50% 43% 40% 0.77
 Hypertension (%) 82% 84% 82% 0.97
 CAD (%) 18% 28% 18% 0.73
 Diabetes (%) 42% 38% 36% 0.88
 Body Mass Index (kg/m2) 29.2 32.4 31.5 0.18
 Hematocrit (%) 41.6% 44.3% 39.95% 0.63
 hsCRP (mg/L) 2.73 2.93 3.87 0.70
PFA-100 Epi (n=71) Responders (n=44) Initial PR (n=20) Persistent PR (n=7) P
 Age (yrs) 64.6 63.5 66.4 0.55
 Race (% Black, White, Hispanic) 25%, 61%, 14% 15%, 80%, 5% 14%, 72%, 14% 0.64
 ASA dose (% 325 mg) 86% 75% 86% 0.52
 Clopidogrel use (%) 25% 35% 14% 0.52
 NSAID use (%) 20% 20% 0% 0.59
 History of Smoking (%) 91% 95% 86% 0.73
 Current Smoking (%) 43% 58% 33% 0.52
 Hypertension (%) 82% 80% 86% 0.94
 CAD (%) 30% 15% 14% 0.46
 Diabetes (%) 40% 30% 57% 0.44
 Body Mass Index (kg/m2) 29.8 28.9 31.3 0.60
 Hematocrit (%) 41.3% 39.3% 42.3% 0.80
 hsCRP (mg/L) 2.93 2.73 3.43 0.49